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Metallothioneins (MT) are cysteine-rich intracellular proteins that sequester epoxides, 
such as the genotoxic styrene metabolite, styrene oxide (SO).  Covalent adduct formation 
by the ring-opening of SO and its homologue, 1-phenylpropylene oxide (trans), with MT 
forms stable complexes that potentially may serve as biomarkers for epoxide exposure.  
MT was reacted with SO and trans-phenylpropylene oxide (PPO) separately in water.  
Mass spectra of adducts were obtained using electrospray ionization with positive-ion 
detection in an ion trap mass spectrometer.  MS/MS analysis established the covalent 
nature of the complexation.  Further experiments were conducted to determine the site of 
adduct formation.  Molecular modeling was used to predict the most likely site of adduct 
formation.  Alkylation and digestion were used to locate the peptide fragment where 
adduct formation occurred and confirm modeling results.  The likeliest cysteine residue 
was residue 48 in the alpha domain of MT.  MT-SO adducts provide a basis for the 
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Metallothioneins are small intracellular cysteine-rich proteins 60-62 amino acid 
residues in size.  Metallothioneins have been found in practically all life forms and have 
been isolated from different organs such as the liver, kidney, and brain (Sanz-Nebot, 
2003).  In mammals, the two major isoforms, MT1 and MT2, are the most abundant in 
the liver, kidney, pancreas, and intestines (Zangger, 2001).   
The conventional nomenclature division of MT1 versus MT2 refers to the absence 
(MT1) or presence (MT2) of an acidic amino acid residue in position 10 or 11 of the 
protein sequence (Sanz-Nebot, 2003).  Isoforms with minor differences are detected as 
subgroups of the two main isoforms (MT1 and MT2).  The subgroup’s specific biological 
roles still remain unknown.    
Mammalian metallothionein binds 7 divalent metal ions to its 20 cysteine residues 
(Hong, 2001).  Metallothionein is comprised of two globular domains.  The N-terminal β-
domain, residues 1-30, binds three metals to nine cysteine residues in a cluster formation.  
The C-terminal α-domain, residues 31-61, binds four metals to eleven cysteine residues 
in another cluster formation (Zangger, 2001). 
  Metallothioneins are believed to play a physiological role in the metabolism of 
toxic metals including zinc, copper and cadmium (Gehrig, 1999).  Metallothionein has 
also been shown to be involved in cellular defense mechanisms associated with oxidation 
and stress (Koh, 2001).  Overexpression of metallothioneins is readily induced by a 
variety of endogenous and exogenous chemicals and elevated metallothionein levels have 
been correlated with resistance to electrophilic molecules used in chemotherapy (He, 
2000).  The proposed mechanism is that increased amounts of metallothionein provide 
increased intracellular drug sequestration, thus reducing the amount reaching the target 
DNA (Zaia, 1996). 
Metallothionein has been previously shown to form covalent adducts with various 
therapeutic agents.  These include chlorambucil (Zaia, 1996), the anticancer agent 
melphalan (Yu, 1995), the nitrogen mustard mechlorethamine (Antoine, 1998), and 
phosphoramide mustard (Wei, 1999). 
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Styrene is a widely used industrial chemical.   Chronic exposure to styrene has 
been shown to produce reproductive, developmental, genotoxic, and carcinogenic effects 
in laboratory animals (Linhart, 2001).  Styrene’s main metabolite, styrene oxide (SO), is 
considered to be responsible for the toxic effects of exposure to styrene.  The epoxide is 
formed from styrene through microsomal monooxygenase (Watabe, 1981). 
 Smoking of methamphetamine hydrochloride laced tobacco yields several volatile 
products formed through pyrolysis.  One such product is 1-phenylpropene (Sato, 2001).  
trans-phenylpropylene oxide (PPO) is a metabolite of 1-phenylpropene as well as a 
homologue of styrene oxide.  The objective of our experiments was to form adducts 
between styrene oxide and trans-phenylpropylene oxide with metallothionein.   
Various analytical techniques have been used to characterize metallothionein.  
Isoelectric focusing has been used to separate isoforms of rabbit metallothionein 
(Nordberg, 1972).  Matrix-assisted laser desorption ionization (MALDI) mass 
spectrometry has been used to study the interaction of sulfur mustard exposure with 
metallothionein (Price, 2000).  Metallothionein dimers have been characterized by nano-
spray mass spectrometry (Hathout, 2002).  Liquid chromatography and capillary 
electrophoresis are also techniques employed to characterize metallothioneins (Dabrio, 
2002).   
The analytical technique used to characterize metallothionein adduct formation 
was mass spectrometry.  Mass spectrometry affords a sensitive and selective mode of 
analysis.  In particular, electrospray ionization mass spectrometry (ESI) was utilized for 
these experiments.  Electrospray ionization is very useful for samples containing large, 
non-volatile molecules such as proteins (Prange, 2002). 
For electrospray ionization, a solution containing the sample and electrolytes is 
pumped through a metal capillary needle that has a high potential applied to it.  The 
electric field at the tip of the capillary needle generates an aerosol of charged droplets.  
These droplets are attracted to an orifice in the interface that carries an opposite charge 
from that of the capillary needle.  As the droplets flow toward the orifice, the droplets 
desolvate, leaving behind charged ions. 
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Electrospray ionization is a soft ionization technique that keeps the molecular 
structure of the proteins intact.  Thus, molecular and structural information can be 
obtained.  
Once adduct formation is established, the next step is to locate the site of adduct 
formation.  This can be done in a variety of ways.  One approach is to use molecular 
modeling to predict where adduct formation occurs.  The modeling predictions are then 
confirmed experimentally.  For example, the protein could be digested and sequenced to 
verify the modeling results. 
Molecular modeling has become an important and powerful tool in understanding 
the structure of proteins.  Molecular structure conformations are simulated using a 
molecular mechanics approach with force field based calculations. The force field 
represents energy calculations that contain information such as bond lengths, bond 
angles, and torsion angles.  Reactions can be modeled in silico to view predicted 
information on atomic motions that can not be readily observed experimentally.  
Comparison to experimental data, where available, is then done to confirm modeling 
predictions.  Structural studies of metallothionein have been done using molecular 
modeling (Rigby, 2004), and modeling has also been used to study drug interactions with 
metallothionein (Szilagyi, 2000). 
As previously stated, the objective of these experiments was to form covalent 
adducts between styrene oxide and trans-phenylpropylene oxide with metallothionein.  
The formation of adducts between metallothionein and styrene oxide or trans-
phenylpropylene oxide could further demonstrate the function of metallothionein in the 
body.  Metallothionein-styrene oxide adducts may also provide a basis for the 




2.  Methods and Materials 
Chemicals and Reagents.  Metallothionein-I from rabbit liver was purchased from 
Sigma Chemical.  The metal content of Metallothionein-I from rabbit liver is 
approximately 7% of cadmium and zinc.  Metallothionein-I is essentially salt free.  
Styrene oxide and trans-phenylpropylene oxide were purchased from Aldrich Chemical.  
Dithiothreitol, guanidine hydrochloride, and Tris buffer were purchased from Sigma 
Chemical.  Trifluoroacetic acid and ethylenediaminetetraacetic acid (EDTA) were 
purchased from Fisher Chemical.  Acetonitrile and methanol were HPLC grade and were 
purchased from Fisher Chemical.  Methyl 4-nitrobenzenesulfonate was purchased from 
Aldrich Chemical.   
The one milliliter C18 solid phase extraction cartridges were purchased from 
Varian Corporation.  The PD-10 desalting columns were purchased from Amersham 
Biosciences.   
Metal Removal Process.  apo-Metallothionein was obtained through a treatment 
process of the purchased metallothionein-I based on a literature method (Zaia, 1998).  
apo-MT-I was prepared by adding trifluoroacetic acid solution (0.02%) to MT-I in water 
(100 µg, 16 µM).  The sample was thoroughly mixed and allowed to sit at room 
temperature for one-half hour.  The metals were removed by solid phase extraction.  A 
one milliliter C-18 extraction cartridge was first conditioned by allowing two one-
milliliter portions of methanol to flow through the cartridge, followed by two one-
milliliter portions of water.  The sample was loaded onto the cartridge and allowed to 
flow completely through.  The cartridge was then washed with two two-hundred 
microliter washes of 0.1% trifluoroacetic acid.  The sample was eluted from the cartridge 
by one two-hundred microliter elution of an acetonitrile: water (30:70) mixture.  
Adduct Formation.  The procedure for forming adducts between metallothionein 
and styrene oxide was a simple mixture step based on a method for forming glutathione-
styrene oxide adducts (Ishida, 1989).  Styrene oxide (500 µg, 4.2 mM) was added to a 
MT-I sample (100 µg, 16 µM).     The sample was rocked for one-half hour at room 
temperature.  Following the mixing step, the samples were taken through the metal 
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removal process.  Twenty microliters of 10 mM ammonium acetate was added to the 
sample and mixed before infusion into the mass spectrometer.  
The method for forming adducts between apo-metallothionein and styrene oxide 
was similar to the procedure for metallothionein.  Styrene oxide (500 µg, 4.2 mM) was 
added to the apo-metallothionein (100 µg, 16 µM) sample and mixed for one-half hour at 
room temperature.  In a test to increase adduct formation, DTT (0.046 mg, 0.3 mM) was 
added to a portion of the samples.  Twenty microliters of 10mM ammonium acetate was 
added to the final sample and mixed before infusion into the mass spectrometer. 
The method for forming adducts between metallothionein and trans-
phenylpropylene oxide was a simple mixture step.  trans-phenylpropylene oxide (0.04 
mg, 0.3 mM) was added to the metallothionein sample (100 µg, 16 µM).  The sample was 
rocked for one-half hour at room temperature and was allowed to stand for 24 additional 
hours at room temperature.  The samples were then taken through the metal removal 
process.  Twenty microliters of 10 mM ammonium acetate was added to the sample and 
mixed before infusion into the mass spectrometer. 
Mass Spectral Analysis of Adduct Formation.  A Finnigan Deca LCQ quadrupole 
ion trap mass spectrometer was used for adduct sample analysis.  The source utilized 
electrospray ionization.  Ions were monitored in the positive ionization mode.  The mass 
analyzer was an ion trap. The samples were infused into the mass spectrometer at a flow 
rate of 7 µL/min.  The heated capillary temperature was 160 °C.  The spray voltage was 
set to 5.21 kV, and the capillary voltage was at 50 V.  The sheath gas flow rate was 39 
mL/min.  MS/MS conditions were 2 amu range on the parent mass and the collision 
energy range was from 30-75%. 
Molecular Modeling.  For the modeling of the styrene oxide adduct, a search was 
first executed at the RCSB Protein Data Bank and only rabbit metallothionein-2 (alpha 
and beta domain) was found.  Next a search was done at the Swiss Prot site for rabbit 
metallothionein-1.  Rabbit metallothionein-1 was located, but there was no 
accompanying PDB file.  Several proteins were considered as surrogates for the structure 
for rabbit metallothionein-1, however, mouse metallothionein-1 was chosen as the 
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starting structure.  All cysteine residues are conserved between mouse MT-1 and rabbit 
MT-1, and mouse MT-1 has 84% homology with rabbit MT-1.  See Table 2.1 for 
comparison of rabbit and mouse metallothionein-1.     
Accelrys’ program Insight II was used for the molecular modeling experiments.  
The downloaded PDB files of mouse metallothionein-1 were separated into the alpha (C-
terminus) and beta (N-terminus) domains.  See Figures 2.1 and 2.2 for the model of the 
alpha and beta domains of mouse metallothionein-1. 
Insight II was used to model the styrene oxide ligand.  Figure 2.3 shows the 
structures for both styrene oxide and trans-phenylpropylene oxide.  The builder module 
was utilized.  An optimization was run on the structure to achieve a low-energy 
confirmation.  First the docking procedure using the Affinity module was followed for 
docking styrene oxide to the mouse metallothionein-1 alpha domain followed by the beta 
domain.  The styrene oxide was positioned close to the cysteine residues.  The active site 
was defined for an area of a 6 Å radius.  The docking was simulated in a vacuum with a 
dielectric constant of 1, and ten structures were accepted.   Docking simulations were 
conducted using a dielectric constant of 80 to simulate water, and ten more structures 
were accepted.  The initial minimization was 100 steps before the simulated annealing 
calculations.  In the simulated annealing estimation the initial temperature was 500 ˚K 
cooling down to 300 ˚K.  The final minimization was 1000 steps using the conjugate 
gradient method.   
Alkylation and Digestion.  To verify the modeling results and to experimentally 
determine where the styrene oxide adducted to the metallothionein, alkylation and 
digestion of the protein was necessary.  Alkylation of the protein was required because of 
a tendency of the cysteine residues to form disulfide bonds, resulting in possible 
formation of false fragments after digestion.  The alkylation and digestion procedure 
utilized was based on previous work (Hunziker, 1991) with modifications (Yu, 1995). 
Samples for MT and MT-SO were prepared as previously described with the 
exception that a desalting column followed by lyophilization was utilized in place of the 
C18 solid phase extraction for metal removal. 
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 For the metal removal using the desalting column, the column was first 
equilibrated with 20 mL of 0.1% (v/v) trifluoroacetic acid (TFA).  The sample was then 
loaded onto the desalting column and eluted with 3.5 mL of 0.1% (v/v) TFA.  Following 
elution, the sample was lyophilized.   
The lyophilized protein was dissolved in 5 mL of buffer solution consisting of 6M 
guanidine HCl, 0.5 M tris/HCl, and 5 mM EDTA, pH 8.6, containing 10 mM DTT.  The 
samples were then immersed in water bath at 37 ˚C for 2 hours.  After incubation, 272 
mM methyl 4-nitrobenzenesulfonate (2.5 mL) was added to the samples and they were 
again immersed in a water bath at 37 ˚C for an additional 6 hours.  The reaction was 
stopped by acidification to pH 2.0 by addition of 20 % TFA, and the mixture was applied 
to a desalting column, and the eluant lyophilized. 
The proteins were digested after dissolving the lyophilized samples in 0.1 M 
ammonium bicarbonate at 1 mg/mL.  Trypsin was added at a 1:50 (w/w) trypsin/protein 
ratio.  The samples were then incubated in a water bath at 37 °C for 2 hours.  The digests 
were refrigerated, desalted as above, and lyophilized. 
Mass Spectral Analysis.  A Finnigan Deca LCQ quadrupole ion trap mass 
spectrometer was used for digest analysis.  The source utilized electrospray ionization.  
Ions were monitored in the positive ionization mode.  The samples were infused into the 
mass spectrometer at a flow rate of 7 µL/min.  The heated capillary temperature was 160 
°C.  The spray voltage was set to 5.21 kV, and the capillary voltage was at 50 V.  The 
sheath gas flow rate was 39 mL/min.   
Molecular Modeling.  To further elucidate which cysteine residue was the site of 
adduct formation, molecular modeling experiments were conducted after the alkylation 
and digestion experiments.  Using Insight II, styrene oxide adducts for both cysteine 
residues 44 and 48 were modeled using the downloaded mouse MT-1 file and 
assimilating the styrene oxide ligand to the cystene residues in question.  Next, a 
minimization using a combination of steepest descent and conjugate gradient for 1000 
iterations was performed on each complex, and the resultant energies of the complexes 





 The major ions in the positive ion ESI spectrum of metallothionein were 1671 (+4 
charge state), 1337 (+5 charge state), and 1115 (+6 charge state).  This calculates to be a 
molecular weight of approximately 6685 for metallothionein (Fig. 3.1).  The major 
charge distribution for MT was at the +6 charge state.  After styrene oxide was adducted 
there was a shift in the spectrum such that the major ions became 1834 (+4 charge state), 
1457 (+5 charge state), and 1230 (+6 charge state) (Fig. 3.2).       
 When metallothionein is taken through the metal removal process the mass 
spectrum simplifies.  The major ions in the spectrum after metal removal were 1561 (+4 
charge state), 1249 (+5 charge state), 1041 (+6 charge state), and 892 (+7 charge state).  
This calculates to be a molecular weight of approximately 6245 (Fig. 3.3).  The major 
charge distribution for apo-MT was at the +5 charge state. 
After adduct formation with styrene oxide, the MT sample went through the metal 
removal process to simplify the spectrum in an attempt to determine the stoichiometry of 
the styrene oxide to metallothionein reaction.  At various charge states (+4 to +7), 
varying amounts of styrene oxide were adducted to the metallothionein (Fig. 3.4). 
  After adduct formation with trans-phenylpropylene oxide, the MT sample went 
through the metal removal process to simplify the spectrum in an attempt to see how 
much trans-phenylpropylene oxide was adducted to the metallothionein.  At various 
charge states (+5 to +7), varying amounts of trans-phenylpropylene oxide were adducted 
to the metallothionein (Fig. 3.5).  The mass comparisons of protein versus adducted 
protein are outlined in Table 3.1. 
After adduct formation with styrene oxide, apo-MT was monitored at various 
charge states (+4 to +6), and styrene oxide was shown to be adducted to the apo-
metallothionein (Fig. 3.6). 
In an attempt to increase adduct formation between apo-MT and styrene oxide, 
dithiothreitol (DTT) was added to the reaction.  Dithiothreitol is a reducing agent that 
minimizes the formation of disulfide bonds between cysteine residues and thereby 
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potentially increases adduct formation with styrene oxide by keeping the cysteine 
residues reduced and available for adduct formation.  The results indicated better adduct 
formation after the addition of DTT (Table 3.1). 
MS/MS experiments were conducted after adduct formation.  Solutions of the 
non-adducted protein and adducted protein were infused separately into the mass 
spectrometer and subjected to varying amounts of collision energy.  The change in mass 
from precursor to product ion were similar (m/z approximately 288) for the non-adducted 
protein and adducted protein for both SO and PPO (Table 3.2).  When using increasing 
collision energies (30, 60, and 75 %) similar fragment patterns were also achieved.  See 
Figures 3.7, 3.8, and 3.9 for MS/MS of metallothionein-I and the SO and PPO adducts at 
the +5 charge state. 
For molecular modeling of metallothionein-I/styrene oxide adduct formation, the 
output from the runs was examined using the Insight II analysis module for alpha and 
beta domain adducts.  The beta domain total energies were consistently lower than the 
alpha domain total energies (Table 3.3).  According to the original hypothesis for the 
project the lower total energies should point to where adducts would most likely form.  
Next, protein-ligand bond distances were considered in adduct formation. 
 The protein-ligand bond distances considered were from the docking simulation 
where the dielectric constant was set to 80, simulating water.  The experimental reaction 
was in water and so this particular simulation was chosen.  Protein-ligand bond distances 
of less than 6 Å from a cysteine residue were considered possible sites for adduct 
formation.  For several of the structures multiple cysteine residues met the criteria to be 
sites of adduct formation.  Table 3.4 gives the residue site and protein-ligand bond 
distances for the Alpha domain.  As can be seen from the table, A6, A7, and A18 
(cysteine residues 36, 37, and 48 respectively) stand out for the most potential sites of 
adduct formation.  In addition A14 (cysteine residue 44) also could be a site for adduct 
formation as the protein-ligand bond distances for 2 of the 3 matches were less than 4 Å.   
Table 3.5 gives the protein-ligand bond distances for the beta domain.  Only A5 
(cysteine residue 5) is a potential site for adduct formation.  Most calculated protein-
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ligand bond distances for the beta domain were too long to support adduct formation with 
a cysteine site.   
For the alkylation of the cysteine residues, various alkylating agents were tested.  
Full alkylation of metallothionein-I was achieved using N-ethylmaleimide.  One very 
important factor in not incorporating N-ethylmaleimide into the final alkylation and 
digestion procedure was that the reaction is reversible (Shaw, 1997).  The next alkylating 
agent tested was iodoacetamide (Bernhard, 1991).  Iodoacetamide, however, only 
partially alkylated the protein.  The final alkylating agent tested was methyl 4-
nitrobenzenesulfonate.  The alkylation with methyl 4-nitrobenzenesulfonate was still only 
partially complete, but to a greater extent than with the iodoacetamide. 
The experimental confirmation of adduct formation suggests that formation 
occurs in the 44-51 peptide fragment of MT-1, which has an expected m/z of 825 (Table 
3.6).  When this fragment is successfully alkylated, the m/z of 867 corresponds to the 
three cysteine residues in the fragment being methylated (Fig. 3.10).  Ions were observed 
at the expected m/z of 867 for the control sample (unadducted MT-I).  An ion was 
observed at 973 for the SO adducted sample (Fig. 3.11).  This ion corresponds to the 
addition of one SO and two methyl groups to the MT-I fragment 44-51 (Fig. 3.12).  
These experimental results were repeated and yielded the same result.  This fragment 
result supports the modeling results for cysteine residue 48, or possibly cysteine residue 
44. 
 The results from modeling the styrene oxide adducts on cysteine residues 44 and 
48 of the alpha domain support the hypothesis of preferential adduct formation on residue 
48 (see Fig. 3.13).  After optimization, the van der Waals energy for adduct formation at 
cysteine residue 44 was 487.6 kcal/mol, as compared to 120.7 kcal/mol for cysteine 
residue 48.  The total energy for adduct formation at cysteine residue 44 was 504.1 
kcal/mol, as compared to 302.4 kcal/mol for cysteine residue 48. 
 
3.2 Discussion 
 A characteristic of electrospray ionization is the spectrum represents an intact 
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molecule carrying differing numbers of charges.  These ions arise from the molecule 
having multiple protonations or attachment of multiple cations (in positive ion mode).  A 
shift in the charge state is possible, and can be the result of a change in solvent polarity or 
a loss of non-covalently bound atoms from the analyte resulting in a lower charge state 
distribution (Cole, 2000).  A small charge state distribution shift was observed for MT 
versus apo-MT with a shift from the +6 to the +5 charge state, which could be due to loss 
of metals.   
For styrene oxide, it was not determined in these experiments which carbon binds 
to the metallothionein.  Either 1-phenyl-2-hydroxyethyl-MT or 2-phenyl-2-hydroxyethyl-
MT could have formed. 
Metallothionein forms adducts with styrene oxide (SO) and trans-
phenylpropylene oxide (PPO).  Adducts with SO and PPO were detected at all charge 
states identified for MT-I.   
An additional experiment was conducted at this time under the previously 
described conditions to attempt to form adducts between styrene and metallothionein.  
MS experiments indicated no adduct formation between styrene and MT, as the spectrum 
remained unchanged from the control.   
apo-Metallothionein forms an adduct with SO.  For apo-metallothionein, the 
addition of reducing agent, DTT, showed increase of adduct formation with SO.  In the 
presence of DTT the stoichiometry of styrene oxide to metallothionein increased to 3-4 
molecules versus 1-2 molecules in the absence of DTT.  apo-Metallothionein adducts 
with SO were detected at all charge states identified. 
MS/MS experiments indicated the covalent nature of adduct formation of 
SO/PPO with metallothionein/apo-metallothionein.  The change in mass from precursor 
to product ion is similar (m/z approximately 288) for the non-adducted and adducted 
protein for both SO and PPO.  When using increasing collision energies (30, 60, and 
75%) similar fragment patterns are achieved (Table 3.7), although the signal intensity 
lessens with increased collision energy.  If the bond were non-covalent in nature, the loss 
of the styrene oxide mass would be expected at each charge state based on lower 
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dissociation energy associated with fragmenting non-covalent adducts in comparison 
with the energy required to fragment covalent bonds.  The dissociation energy for a 
covalent C-N bond is 305 kJ/mol, and the dissociation energy for a covalent C-S bond is 
280 kJ/mol.  A loss corresponding to styrene oxide was not observed in any of the 
MS/MS experiments.   
The identity of the MS/MS product ion loss (m/z approximately 288) is still not 
known.  It is possible that the fragment is a -Met-Asp- fragment from the N-terminal end 
of metallothionein.  Mammalian metallothioneins are characteristically N-acetylated 
(Beattie, 1999), and the presence of an acetyl group could yield a loss corresponding to 
an observed m/z loss of 288 with the formation of a ketene (Fig. 3.14).   
The data from the molecular modeling lead to the conclusion that even though the 
energy is lower for the beta domain, adduct formation is more likely to occur in the alpha 
domain for mouse metallothionein-1.  Four potential sites for adduct formation in the 
alpha domain were identified at cysteine residues 36, 37, 44 and 48.  These simulations 
did not narrow the reactive site of the protein to a single cysteine residue.   
A similar experiment was performed by Szilagyi and Fenselau using rat 
metallothionein-2 to form adducts with nitrogen mustard drugs (Szilagyi, 2000).  The 
simulations also used Insight II.  The cysteine residues at 33 and 48 in the alpha domain 
were found to be the most favorable for adduct formation.  The criteria used were lower 
energy and bond lengths less than 4 Å.  
Our calculations agree with the prediction of Szilagyi and Fenselau in that 
cysteine residue 48 is a favored site for adduct formation.  In contrast cysteine residue 33 
was not identified as a favored reaction site.  Besides the obvious differences in proteins 
and ligands between the experiments, Szilagyi and Fenselau used explicit solvent 
information in their simulation.  Their system was surrounded by water.  This calculation 
method provides a better evaluation of electrostatic forces which are important in ligand-
receptor interactions.  Future experiments could be repeated using explicit solvent 
information to verify the prediction of the active sites for metallothionein. 
The alkylation and protein digestion experiments indicate that adduct formation 
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occurs in the 44-51 peptide fragment of MT-1.  Masses were observed at the expected 
m/z of 867 for the control sample (unadducted MT), and a mass was observed at 973 for 
the SO adducted sample indicating the addition of one SO.  The experimental results are 
consistent with the modeling results.  Further work to clarify adduct formation to the 
exact residue could be done using liquid chromatography with tandem mass spectrometry 
to separate peptide fragments and fully sequence them. 
The results from modeling the styrene oxide adducts on cysteine residues 44 and 
48 of the alpha domain again support the hypothesis of preferential adduct formation on 
residue 48.  The residue with the lower total energy, cysteine residue 48, would be the 
more favorable site for adduct formation.  In addition, from the modeling information, 
adduct formation on cysteine residue 48 is less sterically hindered than on cysteine 
residue 44 as the van der Waals energy differences indicate.  
The stable nature of the adduct formation with SO and PPO with metallothionein 
and apo-metallothionein makes them ideal candidates as potential biomarkers. 
 
4. Summary and Conclusions 
Metallothioneins (MT) are intracellular, low molecular weight, cysteine-rich 
proteins that efficiently sequester epoxides, such as the genotoxic styrene metabolite, 
styrene oxide (SO).  We hypothesized that covalent adduct formation by the ring-opening 
of SO and its homologue, trans-phenylpropylene oxide (PPO), with MT forms stable 
complexes that may serve as potential biomarkers for exposure to styrenes.  MT was 
reacted with SO or PPO in water.  After the MT reaction with SO and PPO, metals were 
removed prior to mass spectral analysis.  Mass spectra were obtained under electrospray 
ionization conditions with positive-ion detection in an ion trap mass spectrometer.  Mass 
spectra of MT-SO and MT-PPO showed that adducts were present in all charge states 
detected.  MS/MS analysis indicated the covalent nature of the complexation.  Further 
experiments were conducted to determine the site of adduct formation.  Molecular 
modeling utilizing Insight II was used to predict the most likely site of adduct formation.  
Alkylation and digestion of MT and MT-SO were used to locate the peptide fragment 
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where adduct formation occurred and additionally confirm the modeling results.  The 
likeliest cysteine residue for adduct formation was residue 48 in the alpha domain of MT-
I.  MT-styrene oxide adducts can provide a basis for the development of biomarkers for 
exposure to epoxides. 
 
 
Table 2.1: Amino Acid Sequence Comparison of Mouse to Rabbit MT-1 
*The A designation is domain position, and the (number) designation is total protein position.   
Beta Domain Alpha Domain 
Residue* Type (mouse-1) Type 
(rabbit-1) 
Residue* Type (mouse-1) Type 
(rabbit-1) 
A1 (1) MET MET A1 (31) LYS LYS 
A2 (2) ASP ASP A2 (32) SER SER 
A3 (3) PRO PRO A3 (33) CYS CYS 
A4 (4)  ASN ASN A4 (34) CYS CYS 
A5 (5) CYS CYS A5 (35) SER SER 
A6 (6) SER SER A6 (36) CYS CYS 
A7 (7) CYS CYS A7 (37) CYS CYS 
A8 (8) SER ALA A8 (38) PRO PRO 
A9 (9) THR THR A9 (39) VAL ALA 
A10 (10) GLY GLY A10 (40) GLY GLY 
A11 (11) GLY ASN A11 (41) CYS CYS 
A12 (12) SER SER A12 (42) SER THR 
A13 (13) CYS CYS A13 (43) LYS LYS 
A14 (14) THR THR A14 (44) CYS CYS 
A15 (15) CYS CYS A15 (45) ALA ALA 
A16 (16) THR ALA A16 (46) GLN GLN 
A17 (17) SER SER A17 (47) GLY GLY 
A18 (18) SER SER A18 (48) CYS CYS 
A19 (19) CYS CYS A19 (49) VAL ILE 
A20 (20) ALA LYS A20 (50) CYS CYS 
A21 (21) CYS CYS A21 (51) LYS LYS 
A22 (22) LYS LYS A22 (52) GLY GLY 
A23 (23) ASN GLU A23 (53) ALA ALA 
A24 (24) CYS CYS A24 (54) ALA SER 
A25 (25) LYS LYS A25 (55) ASP ASP 
A26 (26) CYS CYS A26 (56) LYS LYS 
A27 (27) THR THR A27 (57) CYS CYS 
A28 (28) SER SER A28 (58) THR SER 
A29 (29) CYS CYS A29 (59) CYS CYS 
A30 (30) LYS LYS A30 (60) CYS CYS 
   A31 (61) ALA ALA 































































ND 1671 1337 1114.8 948.7 
      
 +2 SO ND 1297 1081 ND 
 +3 SO 1621 1321 1101 944 
MT-SO +4 SO 1681 1345 1121 961 
 +5 SO 1711 1369 1141 978 
 +6 SO 1741 1393 1161 ND 
 +7 SO 1771 1417 1181 ND 
      
 +1 PPO 1594 1276 1063 911 
MT-PPO +2 PPO 1628 1303 1086 930 
 +3 PPO 1661 1329 1108 950 
 +4 PPO 1695 1356 1130 969 
apoMT n/a 1561 1249 1041 892 
      
apoMT-SO +1 SO 1591 1273 1061 ND 
 +2 SO 1621 1297 1081 ND 
       
 +1 SO 1591 1273 1061 ND 
apoMT-SO 
(DTT) 
+2 SO 1621 1297 1081 ND 
 +3 SO 1651 1322 1101 ND 
 + 4 SO 1681 1345 n/a ND 
ND = not detected 
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Table 3.2: Product vs. Precursor Ions for Various Charge States of Metallothionein 
Adducts 
 
 +5 charge state +6 charge state +7 charge state 
Sample Precursor Product Precursor Product Precursor Product 




















ND = not detected
 
 22
Table 3.3: Total Energies of Final structures for Alpha and Beta Adducts 
 
Mouse-I Energy Energy Energy Energy 








1 437.4590 369.8630 344.4770 307.1810 
2 440.9780 370.9230 346.6740 308.4490 
3 441.3430 372.1730 349.5620 309.0830 
4 442.6950 372.6940 350.0410 310.7720 
5 444.3390 373.9290 352.2860 313.9340 
6 444.4920 374.6710 353.2320 314.0260 
7 444.7340 375.8580 355.6810 315.9610 
8 447.8670 376.2370 355.9450 315.9990 
9 450.4120 376.5850 359.0570 316.3760 























1 A4/2.55 A7/4.58 A14/3.06 A18/4.10   
2 A4/4.31 A6/5.87 A7/2.99 A14/4.52 A29/5.96 A30/5.42 
3 A18/5.91      
4 A18/4.82      
5 A6/5.65      
6 A6/3.06 A7/5.87 A20/4.00 A29/4.28   
7 NONE      
8 A6/5.49 A14/3.18 A18/4.55 A30/4.38   
9 NONE      

















1 A5/4.22 A7/4.23 A24/5.86 A26/3.06 
2 A5/4.75    
3 A5/4.43 A13/4.97 A26/4.40  
4 NONE    
5 NONE    
6 NONE    
7 A5/4.61    
8 NONE    
9 NONE    






Table 3.6:  Metallothionein-I Peptide Mapping 


















825 867 (+3 methyl) 










Table 3.7:  Collision Energy Comparison of Precursor vs. Product Ions at +5 










30% 1191.7 5.8 x 105
60% 1191.9 1.7 x 105
MT 1248.9 
75% 1191.7 4.5 x 104
30% 1239.3 1.0 x 105
60% 1239.1 4.1 x 104
MT-SO 1297.6 





Figure 3.1 Mass Spectrum of Metallothionein-I 
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Figure 3.2 Mass Spectrum of Metallothionein-I/Styrene oxide Adduct
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Figure 3.3 Mass Spectrum of apo-Metallothionein-I  
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Figure 3.5 Mass Spectrum of MT-I/PPO Adduct after Metal Removal
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Figure 3.6 Mass Spectrum of apoMT-I/SO Adduct
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1064.82 1461.40968.68 1335.49614.50 1596.02 842.40 1776.87 1950.56
 
Figure 3.8 MS/MS of MT-I/SO Adduct at +5 Charge State 
 (Precursor 1273)
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1065.10 1365.57 1521.00 
614.50 913.60813.62 1700.63 422.46 
M-288
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Figure 3.10 Mass Spectrum of Metallothionein-I Digest
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Figure 3.11 Mass Spectrum of MT-I/SO Adduct Digest
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